Benjamin Palleiko - Kalvista Pharmaceuticals Chief President
| KALV Stock | USD 11.89 0.11 0.92% |
President
Mr. Benjamin L. Palleiko is Chief Financial Officer, Chief Business Officer of KalVista Pharmaceuticals, Inc. Mr. Palleiko was hired as Chief Financial Officer of KalVista Limited in August 2016 and was appointed as our Chief Financial Officer in November 2016 in connection with the reverse acquisition transaction. Prior to joining us, Mr. Palleiko was a Managing Director of H.C. Wainwright Co. LLC since January 2015. Mr. Palleiko also cofounded a private oncology drug development company, Cielo Therapeutics, Inc., in July 2012. Mr. Palleiko served as Chief Financial Officer of Nostrum Pharmaceuticals LLC, a specialty generic pharmaceuticals company, from January 2012 to December 2013. He previously was Senior Vice President and Chief Financial Officer of Ore Pharmaceutical Holdings Inc. and Penwest Pharmaceuticals Co. Earlier in his career Mr. Palleiko was an investment banker with the firms Robertson Stephens and SunTrust Robinson Humphrey since 2019.
| Age | 59 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Address | 55 Cambridge Parkway, Cambridge, MA, United States, 02142 |
| Phone | 857 999 0075 |
| Web | https://www.kalvista.com |
Benjamin Palleiko Latest Insider Activity
Tracking and analyzing the buying and selling activities of Benjamin Palleiko against Kalvista Pharmaceuticals stock is an integral part of due diligence when investing in Kalvista Pharmaceuticals. Benjamin Palleiko insider activity provides valuable insight into whether Kalvista Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Kalvista Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Kalvista Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Benjamin Palleiko few days ago Acquisition by Benjamin Palleiko of 9363 shares of Kalvista Pharmaceuticals subject to Rule 16b-3 | ||
Benjamin Palleiko over a week ago Acquisition by Benjamin Palleiko of 30195 shares of Kalvista Pharmaceuticals subject to Rule 16b-3 | ||
Benjamin Palleiko over two weeks ago Disposition of 6669 shares by Benjamin Palleiko of Kalvista Pharmaceuticals at 11.97 subject to Rule 16b-3 | ||
Benjamin Palleiko over two weeks ago Disposition of 15625 shares by Benjamin Palleiko of Kalvista Pharmaceuticals subject to Rule 16b-3 |
Kalvista Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.5815) % which means that it has lost $0.5815 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.505) %, meaning that it created substantial loss on money invested by shareholders. Kalvista Pharmaceuticals' management efficiency ratios could be used to measure how well Kalvista Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Kalvista Pharmaceuticals' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 0.17 in 2025, despite the fact that Return On Tangible Assets are likely to grow to (1.03). At this time, Kalvista Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 11.7 M in 2025, despite the fact that Return On Tangible Assets are likely to grow to (1.03).Similar Executives
| Found 10 records | PRESIDENT Age | ||
| Deanna Weber | Gossamer Bio | N/A | |
| Ching Jaw | Cytokinetics | 61 | |
| Robert Wong | Cytokinetics | 58 | |
| Neil MD | Syndax Pharmaceuticals | 60 | |
| Christian Waage | Gossamer Bio | 57 | |
| Stephen Betz | Crinetics Pharmaceuticals | 59 | |
| Andrew McKibben | Mirum Pharmaceuticals | N/A | |
| Ashish Mandelia | Mersana Therapeutics | 50 | |
| Deborah Knobelman | Kronos Bio | 51 | |
| Brian DeSchuytner | Mersana Therapeutics | 46 | |
Management Performance
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.58 |
Kalvista Pharmaceuticals Leadership Team
Elected by the shareholders, the Kalvista Pharmaceuticals' board of directors comprises two types of representatives: Kalvista Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kalvista. The board's role is to monitor Kalvista Pharmaceuticals' management team and ensure that shareholders' interests are well served. Kalvista Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kalvista Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jarrod Aldom, Vice Communications | ||
| Nicole Sweeny, Chief Officer | ||
| Ryan Baker, Head Relations | ||
| Benjamin Palleiko, Chief President | ||
| Brian Piekos, Chief Officer | ||
| John McKune, VP Fin | ||
| Thomas MBA, CEO Director | ||
| Michael PharmD, Senior Development | ||
| Christopher Yea, Chief Development Officer | ||
| MD MBA, Chief Officer | ||
| Jeb Ledell, Chief Officer | ||
| Stephen Donnelly, Director Secretary | ||
| Rachel Morten, Senior QA | ||
| Edward Feener, Chief Scientific Officer | ||
| Brian JD, General Counsel |
Kalvista Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kalvista Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.58 | ||||
| Current Valuation | 344.69 M | ||||
| Shares Outstanding | 49.72 M | ||||
| Shares Owned By Insiders | 1.36 % | ||||
| Shares Owned By Institutions | 98.64 % | ||||
| Number Of Shares Shorted | 5.83 M | ||||
| Price To Earning | (2.82) X | ||||
| Price To Book | 4.08 X | ||||
| Price To Sales | 107.42 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Kalvista Stock Analysis
When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.